Cellectis (CLLS) Reports Q4 EPS of EUR0.59
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Cellectis Reports Fourth Quarter and Full Year 2015 Financial Results
March 14, 2016 5:19 PM EDT- On track with submission of UCART19 Clinical Trial Application; Application Filed with MHRA (UK)
- Encouraging data from the First-in-Human compassionate use of UCART19
- Early opt-in by Servier into UCART19; amendment with improved economics
- Successful production of UCART19 batches in GMP conditions; the first
off-the-shelf UCART product candidate
- On track with GMP UCART123 production; IND filing expected later in 2016
- FY2015 Revenues and other income of $61.4 million (56.4 million), with an adjusted net income of $10.3 million (9.5 million)
- Strong... More
